DESIGN AND IN VITRO EVALUATION OF EXTENDED RELEASE TABLET OF NATEGLINIDE
The aim of present study is to formulate and evaluate extended release matrix tablet of Nateglinide by direct compression method using different polymer like HPMC K4 and HPMC K15. Matrix tablet of nateglidine were prepared in combination with the polymer HPMC K4, HPMC K15, along with the excipients and the formulations were evaluated for tablet properties and in vitro drug release studies. Nateglinide matrix tablet prepared by using polymer such as HPMC K4 and HPMC K15, it was found that HPMC K15 having higher viscosity as compare to HPMC K4 therefore different concentration of polymer were studied to extend the drug release up to 12 h. The tablets of Nateglinide prepared by direct compression had acceptable physical characteristics and satisfactory drug release. The study demonstrated that as far as the formulations were concerned, the selected polymers proved to have an acceptable flexibility in terms of in-vitro release profile. In present the study the percent drug release for optimize batch was found to 94.62%. Hence it can be conclude that Nateglinide extended release matrix tablet can prepared by using HPMC. The swollen tablet also maintains its physical integrity during the drug release study
Keywords: Tablet, in-vitro drug release, Nateglinide, HPMC
2. Amaral MH, Sousa Lobo JM, Ferreira DC. Naproxen availability from variable dose and wet sustained released tablets, Drug Dev. Ind. Pharmacy.2001; 13:123-133.
3. Kumar, M.N.V.R. and N. Kumar. Polymeric controlled drug delivery systems: perspectives issues and opportunities. Drug Dev. Ind. Pharm. 2001; 27:1-30.
4. Dixit N Sustain release drug delivery system. Indian J Res. Pharmacy and Biotech 2013; 1(3):305 – 310.
5. Rother KI . "Diabetes treatment— bridging the divide", The New England Journal of Medicine. 2007; 356(15
6. Dey HB, Kumar S, Kumar D, Formulation, Characterization and invitro evaluation of Floating microspheres of Nateglinide. Int. J Pharma & Bio Sciences; 2011, P147.
7. C. V. S. Subramanyam, Textbook of Physical Pharmaceutics, Vallabh Prakashan 9thedition 2008, pp181-225.
8. Lieberman HA ,Lachman L, Pharmaceutical dosage form; Tablet 2nd edition, Marcel and Dekker ,New York
9. Barde L N, Wadekar A B, Aher S R, Thenge R R, Formulation and Evaluation of Extended Release Tablet of Metoprolol Succinate. World J Pharm Sci., 2016, 5(6):1302-1316..
10. Patel KB, Vyas JR, Upadhayay UM,” Formulation and Evaluation of Sustained Release Matrix Tablets of Nateglinide”. Journal of Drug Delivery & Therapeutics. 2015; 5(5):19-25. https://doi.org/10.22270/jddt.v5i5.1130
11. Venkateshvarlu K, Formulation and Evaluation of Sustained Release Matrix Tablets of Repaglinide. Bangladesh Pharma Journal, 2016; 19(1):92-99.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).